As part of the
“The scalability and general technology of our genetic test, Prostatype®, are well-suited from a business model perspective for the U.S. market, which is why we have also shifted our focus and strategy to the states. We are close to tapping into a major market, and with Prostatype® being ready for sale, we are even closer to reaching the major milestone of obtaining Medicare approval in Q4 2024. The feedback we have received from American urologists has been overwhelmingly positive, and we are confident in the successful implementation and active use of our genetic test”, says
The next milestone, also being a pre-requisite for Medicare approval, is the completion of interim data with focus on the Afro-American population from the ongoing validation study in the
For more information, please contact:
Telephone: +46 (0)73 049 77 01
Email: fredrik.rickman@prostatypegenomics.com
About
Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at
© Modular Finance, source